Which anti-CGRP monoclonal antibody is marketed as Aimovig?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which anti-CGRP monoclonal antibody is marketed as Aimovig?

Aimovig is the brand name for erenumab, a monoclonal antibody that targets the CGRP receptor and blocks CGRP from activating it. This prevents the CGRP signaling thought to contribute to migraine pathophysiology. The other anti-CGRP antibodies—galcanezumab, fremanezumab, and eptinezumab—bind the CGRP ligand itself rather than the receptor, and are marketed as Emgality, Ajovy, and Vyepti, respectively. So the antibody marketed as Aimovig is erenumab.

Aimovig is the brand name for erenumab, a monoclonal antibody that targets the CGRP receptor and blocks CGRP from activating it. This prevents the CGRP signaling thought to contribute to migraine pathophysiology. The other anti-CGRP antibodies—galcanezumab, fremanezumab, and eptinezumab—bind the CGRP ligand itself rather than the receptor, and are marketed as Emgality, Ajovy, and Vyepti, respectively. So the antibody marketed as Aimovig is erenumab.

More practice questions